Month: May 2020

Orphazyme A/SCompany announcement                                                                                       No. 34/2020                                                                                                          Company Registration No. 32266355      ·EMA Marketing Authorisation Application submission expected in H2 2020Copenhagen, Denmark, May 29, 2020 – Orphazyme A/S (ORPHA.CO), a biopharmaceutical company pioneering the Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, today announces it has initiated the submission of its New Drug Application (NDA) for a rolling review by the US Food and Drug Administration (FDA) for arimoclomol, an investigational Heat-Shock Protein amplifier, for the treatment of Niemann-Pick disease Type C (NPC).Arimoclomol has received FDA Fast Track and...

Geneva, Switzerland and Boston, MA – May 29, 2020 – ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today announced that CEO Ernest Loumaye will present an update on the Company and its pipeline at the Jefferies Virtual Healthcare Conference taking place June 2-4, 2020.Mr. Loumaye’s presentation will take place on Wednesday June 3, 2020 at 8:00 a.m. Eastern Time (ET).  A live presentation link will be available under “Events Calendar” in the investors section of ObsEva’s website at www.ObsEva.comAbout ObsEvaObsEva is a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health and pregnancy. Through strategic in-licensing and disciplined drug development, ObsEva has established...

CAMBRIDGE, Mass., May 28, 2020 (GLOBE NEWSWIRE) — Mersana Therapeutics, Inc. (Nasdaq:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced the pricing of an underwritten public offering of 8,000,000 shares of common stock at a price to the public of $19.00 per share. Gross proceeds to Mersana from the offering are expected to be $152.0 million, before deducting underwriting discounts and commissions and offering expenses payable by Mersana. In addition, Mersana has granted the underwriters a 30-day option to purchase up to an additional 1,200,000 shares of common stock, at the public offering price less underwriting discounts and commissions. All shares are being sold by Mersana....

SHANGHAI, China, May 28, 2020 (GLOBE NEWSWIRE) — Qutoutiao Inc. (“Qutoutiao” or the “Company”) (NASDAQ: QTT), a leading operator of mobile content platforms in China, today announced that it will report its unaudited financial results for the first quarter ended March 31, 2020 before the open of U.S. markets on Thursday, June 4, 2020.Qutoutiao’s management will host an earnings conference call at 7:00 AM U.S. Eastern Time on June 4, 2020 (7:00 PM Beijing/Hong Kong time on the same day).Due to the outbreak of COVID-19, operators to assist conference calls are not available at the moment. To speed up the entry process, all participants who wish to join the call must preregister online to receive the dial-in details.Preregistration InformationParticipants can register for the conference call by navigating to https://apac.directeventreg.com/registration/event/4185245...

TORONTO, May 28, 2020 (GLOBE NEWSWIRE) — Itafos (TSX-V: IFOS) (the “Company”) reported today its Q1 2020 financial results and operational highlights. The Company’s financial statements and management’s discussion and analysis for the three months ended March 31, 2020 are available under the Company’s profile at www.sedar.com and on the Company’s website at www.itafos.com. All dollar values are in thousands of US Dollars except as otherwise noted.Overall HighlightsFor the three months ended March 31, 2020, the Company’s financial highlights were as follows:generated adjusted EBITDA of $(186), representing a 109% decrease year-over-year primarily due to significant and continued downward pressure on diammonium phosphate (“DAP”) New Orleans (“NOLA”) prices to which MAP sales prices are linked;incurred net loss of $18,289, representing...

Not for distribution to U.S. news services or dissemination in the United StatesRICHMOND HILL, Ontario, May 28, 2020 (GLOBE NEWSWIRE) — Canso Select Opportunities Corporation (TSX Venture: CSOC.A, CSOC.B) (the “Company” or “CSOC”) is pleased to announce that it has closed  the  previously announced sale of 112,668 Series 4 Class A preferred shares of Hubba Inc. to Skunkworks Investment Corporation (“Skunkworks”) for total cash consideration to the Company of US$1,823,249.91 pursuant to a share transfer agreement dated March 11, 2020 (the “Transaction”).As at December 31, 2019, the Hubba position accounted for approximately 25.6% of  the  Company’s assets. The Transaction is intended to reduce the Hubba position to 6% of the Company’s assets. The Company wanted to reduce this position and intends to use the gross proceeds from the...

SAN CARLOS, Calif., May 28, 2020 (GLOBE NEWSWIRE) — Iovance Biotherapeutics, Inc. (Nasdaq:IOVA) (“Iovance” or “Company”), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies (tumor-infiltrating lymphocyte, TIL, and peripheral-blood lymphocyte, PBL), today announced the pricing of an underwritten public offering of 16,935,484 shares of its common stock at a public offering price of $31.00 per share.  The gross proceeds from the offering, before deducting the underwriting discounts and commissions and other estimated offering expenses payable by Iovance, are expected to be approximately $525 million.  In addition, Iovance has granted the underwriters a 30-day option to purchase up to 2,540,322 additional shares of common stock at the public offering price, less the underwriting discounts and commissions. ...

CHAMPAIGN, Ill., May 28, 2020 (GLOBE NEWSWIRE) — First Busey Corporation (NASDAQ: BUSE) (the “Company”), the holding company for Busey Bank (the “Bank”), today announced the pricing of its public offering of $125 million aggregate principal amount of 5.25% Fixed-to-Floating Rate Subordinated Notes due 2030 (the “Notes”). The price to the public for the Notes was 100% of the principal amount of the Notes. Interest on the Notes will accrue at a rate equal to (i) 5.25% per annum from the original issue date to, but excluding, June 1, 2025, payable semiannually in arrears, and (ii) a floating rate per annum equal to a benchmark rate, which is expected to be Three-Month Term SOFR (as defined in the Notes), plus a spread of 511 basis points from, and including, June 1, 2025, payable quarterly in arrears. The Notes are intended to qualify...

RADNOR, Pa., May 28, 2020 (GLOBE NEWSWIRE) — Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS) (“Marinus” or the “Company”), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced the pricing of an underwritten public offering of 16,000,000 shares of its common stock at a public offering price of $2.50 per share. The gross proceeds of the offering to the Company are expected to be approximately $40,000,000, before deducting the underwriting discounts and commissions and other estimated offering expenses. In addition, Marinus has granted the underwriters a 30-day option to purchase up to an additional 2,400,000 shares of common stock at the public offering price, less underwriting discounts and commissions.Marinus Pharmaceuticals, Inc. is a pharmaceutical company...

LAKE FOREST, Calif, May 28, 2020 (GLOBE NEWSWIRE) — ToughBuilt Industries, Inc. (“ToughBuilt” or the “Company”) (NASDAQ: TBLT; TBLTW), an advanced product design, manufacturer and distributor with emphasis on innovative products, currently focused on tools and other accessories for the professional and do-it-yourself construction industries, today announced the pricing of an underwritten public offering of 18,000,000 shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) and warrants to purchase up to 18,000,000 shares of the Company’s common stock. Each share of common stock or pre-funded warrant is being sold together with a warrant to purchase one share of common stock. The combined purchase price for one share of common stock and warrant to purchase one share of common stock will be $1.00....